RVMD (STOCKS)
Revolution Medicines, Inc. Common Stock
$203.710000
+1.710000 (+0.85%)
Prev close: $202.000000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals Other
- CEO
- Mark A. Goldsmith, MD, PhD
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $43,643.38M
- Employees
- 809
- P/E (TTM)
- -23.11
- P/B (TTM)
- 16.75
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
10
Strong Buy
16
Buy
2
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Jun 2026 (Q2)
|
$-3.06 | $-2.02 | -1.0427 | -51.69% |
|
Mar 2026 (Q1)
|
$-2.29 | $-1.88 | -0.4140 | -22.07% |
|
Dec 2025 (Q4)
|
$-1.86 | $-1.61 | -0.2477 | -15.36% |
|
Sep 2025 (Q3)
|
$-1.61 | $-1.45 | -0.1627 | -11.24% |
Financial Statements
| Revenues | $0.00 |
| Nonoperating Income/Loss | -$141.04M |
| Operating Expenses | $1.63B |
| Research and Development | $1.30B |
| Other Operating Expenses | $330.91M |
| Operating Income/Loss | -$1.63B |
| Income/Loss From Continuing Operations After Tax | -$1.77B |
| Income/Loss From Continuing Operations Before Tax | -$1.77B |
| Net Income/Loss | -$1.77B |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$1.77B |
| Net Income/Loss Available To Common Stockholders, Basic | -$1.77B |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$8.85 |
| Diluted Earnings Per Share | -$8.85 |
| Basic Average Shares | 599,694,807 |
| Diluted Average Shares | 599,694,807 |
| Assets | $4.32B |
| Current Assets | $4.03B |
| Noncurrent Assets | $294.93M |
| Fixed Assets | $34.61M |
| Intangible Assets | $55.80M |
| Other Non-current Assets | $204.52M |
| Liabilities | $1.72B |
| Current Liabilities | $354.06M |
| Accounts Payable | $88.42M |
| Other Current Liabilities | $265.64M |
| Noncurrent Liabilities | $1.36B |
| Equity | $2.61B |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $2.61B |
| Liabilities And Equity | $4.32B |
| Net Cash Flow From Operating Activities | -$1.22B |
| Net Cash Flow From Operating Activities, Continuing | -$1.22B |
| Net Cash Flow From Investing Activities | -$1.39B |
| Net Cash Flow From Investing Activities, Continuing | -$1.39B |
| Net Cash Flow From Financing Activities | $3.02B |
| Net Cash Flow From Financing Activities, Continuing | $3.02B |
| Net Cash Flow | $413.94M |
| Net Cash Flow, Continuing | $413.94M |
| Comprehensive Income/Loss | -$1.77B |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$1.78B |
| Other Comprehensive Income/Loss | -$952.97M |